Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study

Authors: Chong Yan¹,₉⁺; Rui-Sheng Duan²⁺; Huan Yang³⁺; Haifeng Li⁴; Zhangyu Zou⁵; Hua Zhang⁶; Hongyu Zhou⁷; Xiao-Li Li²; Hao Zhou³; Lidong Jiao⁴; Jialin Chen⁵; Jian Yin⁶; Qin Du⁷; Michael Lee⁸; Yu Chen⁸; Xiaoxiang Chen⁸; Chongbo Zhao¹,₉⁺;

1. Huashan Rare Disease Center, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China;
2. Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China;
3. Department of Neurology, Xiangya Hospital, Central South University, Changsha, China;
4. Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China;
5. Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China;
6. Department of Neurology, Beijing Hospital, Beijing, China;
7. Department of Neurology, West China Hospital, Sichuan University, Chengdu, China;
8. Harbour BioMed, Shanghai, China;
9. National Center for Neurological Disorders, Shanghai, China.

* These authors contribute equally to the present studies.

Correspondence: Chongbo Zhao, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China

E-mail: zhao_chongbo@fudan.edu.cn
Supplemental Materials

Supplemental Table 1 The dose of corticosteroids at baseline

| Dose of corticosteroids at baseline (Prednisone or equivalent) | Batoclimab 680 mg (N=11) | Batoclimab 340 mg (N=10) | Placebo (N=9) |
|---------------------------------------------------------------|----------------------------|----------------------------|---------------|
| 0 - ≤10 mg                                                    | 2                          | 2                          | 2             |
| 10 - ≤20 mg                                                   | 4                          | 1                          | 1             |
| 20 - ≤40 mg                                                   | 2                          | 3                          | 4             |
| 40 - ≤60 mg                                                   | 3                          | 0                          | 0             |
| Total                                                         | 11                         | 6                          | 9             |

Supplemental Table 2 The dose of immunosuppressants at baseline

| Immunosuppressants | Dose  | Batoclimab 680 mg (N=11) | Batoclimab 340 mg (N=10) | Placebo (N=9) |
|--------------------|-------|--------------------------|--------------------------|---------------|
| Azathioprine       | 12.5 mg | 0                        | 0                        | 1             |
|                    | 50 mg  | 1                        | 0                        | 0             |
|                    | 100 mg | 0                        | 1                        | 0             |
|                    | 150 mg | 0                        | 1                        | 0             |
| Tacrolimus         | 1 mg   | 0                        | 0                        | 1             |
|                    | 2 mg   | 0                        | 2                        | 0             |
|                    | 3 mg   | 5                        | 3                        | 0             |
|                    | 4 mg   | 2                        | 1                        | 0             |
|                    | 6 mg   | 0                        | 0                        | 1             |
| Total              | 8      | 8                        | 3                        |               |
### Supplemental Table 3 Thymectomy information at baseline

| Groups         | Subject number | Thymectomy | ICF signature | Interval          |
|----------------|----------------|------------|---------------|-------------------|
| Batoclimab 680mg | XXX            | 2011-03-09 | 2020-11-19     | >9 yrs.           |
|                | XXX            | 2012-10    | 2021-02-24     | >8 yrs.           |
|                | XXX            | 2014-01-24 | 2021-01-06     | 7 yrs.            |
| Batoclimab 340mg | XXX            | 2018-11-14 | 2020-08-13     | 1 yrs.&9 months  |
|                | XXX            | 2012-10    | 2021-03-24     | >8 yrs.           |
|                | XXX            | 2000-08    | 2021-03-16     | >20 yrs.          |
| Placebo        | XXX            | 2016-06    | 2021-03-05     | >4 yrs.           |
|                | XXX            | 2004       | 2021-03-17     | >16 yrs.          |

### Supplemental Table 4 Ethics committee information

| Study Site                                      | Ethics Committee                                                                 | Approval Number |
|------------------------------------------------|-----------------------------------------------------------------------------------|-----------------|
| Huashan Hospital, Fudan University              | Institutional Ethics Committee for Drugs Clinical Trials of Huashan Hospital, Fudan University | 2020-074        |
| The First Affiliated Hospital of Shandong       | Institutional Ethics Committee for Drugs Clinical Trials of The First Affiliated Hospital of Shandong First Medical University | 2020-10         |
| First Medical University                        |                                                                                   |                 |
| Xiangya Hospital, Central South University      | Institutional Ethics Committee of Xiangya Hospital, Central South University       | 202009223       |
| Xuanwu Hospital, Capital Medical University     | Institutional Ethics Committee for Drugs Clinical Trials of Xuanwu Hospital, Capital Medical University | 2020-018        |
| Fujian Medical University Union Hospital        | Institutional Ethics Committee for Drugs Clinical Trials of Fujian Medical University Union Hospital | 2020YW054-01    |
| Beijing Hospital                                | Institutional Ethics Committee of Beijing Hospital                                 | 2020BJYYEC-212-01 |
| West China Hospital, Sichuan University         | Institutional Ethics Committee for Drugs Clinical Trials of West China Hospital, Sichuan University | 2020-156        |
Supplemental figure legends

Supplemental Figure 1 Changes of IgM levels

Serum total IgM levels after batoclimab and placebo treatment over the whole study period. Values are mean±standard error, expressed as the concentrations change from baseline.